Slide 1: Investor Presentation March 2012
Investor Presentation March 2012
Slide 2: Safe Harbor
SAFE HARBOR Certain statements in this release concerning our future growth prospects are forward- looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 3: Agenda
AGENDA BIOCON SNAPSHOT BRANDED FORMULATIONS STRATEGIC ALLIANCES RESEARCH & DEVELOPMENT FINANCIAL HIGHLIGHTS 3
Slide 4: Biocon Snapshot
BIOCON SNAPSHOT
Slide 5: Introduction
INTRODUCTION Biocon is an emerging, global Bio-pharmaceutical enterprise, focused on innovation to develop affordable products and services for patients, partners and healthcare systems across the world. Biocon is committed towards: Reducing therapy costs of chronic diseases. (diabetes, cancer & aut
Slide 6: Business Structure & Holdings
BUSINESS STRUCTURE & HOLDINGS BIOPHARMA SUBSIDIARIES Biocon Research , India | 100% R&D- Novel Molecules Biocon Biopharmaceuticals | 100% MAbs and Biosimilars Biocon Sdn. Bhd, Malaysia | 100% Overseas subsidiary ~61% | Promoters Biocon SA, Switzerland | 100% ~7% | Employees & ESOP trust Biocon Overs
Slide 7: A Portfolio Based Approach
A PORTFOLIO BASED APPROACH Insulins & Other Branded Research Novel Statins Immuno Biopharma Formulations Services Molecules Suppressants Portfolio Constituents Statins Simvastatin, Atorvastatin, Lovastatin, Rosuvastatin, Fluvastatin & Pravastatin Insulins & Insulin, Glargine & 2 Analogs (under devel
Slide 8: A Risk Balanced Growth Strategy
A RISK BALANCED GROWTH STRATEGY Small Molecules Research Biosimilars Services (Biologics & Growth Insulins) Verticals Novel Branded Molecules Formulations EMERGING EMERGINGMARKETS MARKETS FOCUS FOCUS 8
Slide 9: Research Services: From Labs to Clinics
RESEARCH SERVICES: From Labs to Clinics 9
Slide 10: Research Services: Value based Positioning
RESEARCH SERVICES: Value based Positioning Integrated Model spanning across discovery & early Component development to late stage clinical studies Play Cluster Play Large Portfolio of Offerings combining Chemistry & Biologics expertise with cost advantage Integrated Custom partnership models ranging
Slide 11: Biosimilar Insulin Portfolio
BIOSIMILAR INSULIN PORTFOLIO Committed to delivering affordable, quality insulin to global markets • rh-Insulin • 30+ registrations in • rh-Insulin: Emerging markets • Phase 3 trial in EU • Commercialized in several • Basal insulin analog geographies • Strong regional partners • Glargine • Rapid act
Slide 12: Diabetes Prevalence
Diabetes Prevalence (% of population) Diabetics (absolute nos. ) Source: International Diabetes Atlas 2011 12
Slide 13: Insulins: Global Opportunity
INSULINS: GLOBAL OPPORTUNITY Total 2011 Insulin Market: USD ~17 Bn USD 13% ~17 Bn rh insulin 23% 20% 17% lispro 14% 43% glargine detemir USD 32% 9% 4% ~15 Bn glulisine 2% aspart 23% 2010 rh Insulin Glargine Lispro Aspart Others 2011 Market Breakup by Molecule Growth Contribution by Molecule Source:
Slide 14: Branded Formulations
BRANDED FORMULATIONS
Slide 15: Branded Formulations: Therapeutic Segments
BRANDED FORMULATIONS : THERAPEUTIC SEGMENTS 15
Slide 16: Branded Formulations: Products & Markets
BRANDED FORMULATIONS : PRODUCTS & MARKETS INDIA PRODUCT RANKINGS* Cardiology Myokinase 2 Oncotherapeutics BioMAb EGFR 2 Abraxane 3 Immunotherapy Tbis 2 Picon 2 * January MAT 2012 16
Slide 17: Biocon's Insulin Business (India)
BIOCON’S INSULIN BUSINESS (INDIA) MAT January 2012 YoY Biocon’s ranking Biocon’s market share by growth for value sales of 40 volume: IU insulin: #4 in overall insulin Market: 16% 40 IU Insulin: 11% #3 in the 40 IU Insulin market 41% Biocon: Glargine vials: 84% #1 in the Glargine vial market Novo No
Slide 18: Branded Formulations: INSUPen ease Launch
BRANDED FORMULATIONS : INSUPen® ease LAUNCH Designed for accuracy, efficiency, safety & economy. • Launched in October, 2011 • Based on proprietary German technology • Reusable delivery device capable of delivering both InsugenTM & BasalogTM • “One Call Does All” Support helpline 18
Slide 19: Strategic Alliances
STRATEGIC ALLIANCES
Slide 20: Strategic Partnerships
STRATEGIC PARTNERSHIPS Amylin Diabetes Peptide Hybrid CIMAb Oncology BioMAb EGFR, Itolizumab Discovery IATRICa Oncology Immuno-conjugated MAbs Vaccinex Oncology Biobetter MAbs First in Class Optimer Fidaxomicin Anti Infective Commercialization Oncology & Mylan Biosimilars Auto Immune Discovery to Re
Slide 21: Biosimilars Commercialization Partnership: Mylan
BIOSIMILARS COMMERCIALIZATION PARTNERSHIP: MYLAN Monoclonal Antibodies (MAbs) Combines Biocon's R&D and manufacturing prowess of novel biologics/ bio-generics with Mylan’s regulatory & commercialization capabilities in the US and Europe Market Value of Portfolio in 2011: ~33 Bn USD Exclusive collabo
Slide 22: Fidaxomycin Commercialization Partnership: Optimer
FIDAXOMYCIN COMMERCIALIZATION PARTNERSHIP: OPTIMER First-in-class Anti-Infective Combines Biocon's R&D and manufacturing prowess of novel biologics/ bio-generics with Optimer’s proprietary molecule technology Exclusive collaboration for manufacture & supply of . TM & DIFICLIRTM tablets Fidaxomicin A
Slide 23: Research & Development
Research & Development
Slide 24: Research Partnerships: High Potential Product Pipeline
RESEARCH PARTNERSHIPS : HIGH POTENTIAL PRODUCT PIPELINE US IND filed by partner (Amylin) for AC165198 Several Bi-specific fusion proteins under development with IATRICa * Including molecules from collaborative programs 24
Slide 25: Anti-CD6 MAb: Itolizumab
ANTI-CD6 MAb: Itolizumab Drug Highlights Targets CD6 CD6 is a type 1 cell membrane glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) super family group B. CD6 is predominantly expressed by T cells & a B cell subset. CD6 binds ALCAM (activated leukocyte cell adhesion molecule) whi
Slide 26: TREAT PLAQ Study: Summary of Results
TREAT PLAQ STUDY: SUMMARY OF RESULTS# PRIMARY ENDPOINT Result* Statistically significant patient cohort with ≥ PASI 75 at 12 Weeks SECONDARY ENDPOINTS Significant Proportion of subjects achieving PASI 50 and PASI 90 Safety & Tolerability Improvement in PGA scores Considerable Proportion of s
Slide 27: TREAT PLAQ Study: Efficacy Results
TREAT PLAQ STUDY : EFFICACY RESULTS Representative patient samples from each arm. Week Baseline 12 Weeks 28 Weeks Trial Arm Induction Dose Arm Fixed Dose Arm Placebo Arm 27
Slide 28: Oral Insulin IN-105
ORAL INSULIN IN-105 Drug Highlights Conjugated peptide Lower immunogenicity and mitogenicity. Comparable safety and good clearance profile. Metabolically equivalent. Monotherapy. Combination therapy with metformin, sulfonylurea, PPAR agonists, DPP4i. Pre-meal insulin in combination with basal insuli
Slide 29: IN-105 India Phase III Result Summary
IN-105 INDIA PHASE III RESULT SUMMARY SECONDARY END POINTS Efficacy – Secondary Endpoints Statistically significant reduction in PPG during STM Significant reduction in SMBG post prandial glucose excursion Safety – Secondary Endpoints No clinically significant hypoglycemia Very low immunogenic
Slide 30: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 31: Top Line & Bottom Line
TOP LINE# & BOTTOM LINE# INR crore / USD mn FY08 FY09 FY10 FY11 Revenue 1090 273 1194 260 1493 318 1834 402 EBITDA 335 83 372 81 455 97 574 126 Net profit 225 56 238 52 273 58 340 74 9M FY12 9M FY11 Revenue 1511 | 319 1355 | 297 EBIDTA 425 | 90 426 | 93 28% 31% PAT 241 | 51 246 | 54 16% 18% EPS 12 1
Slide 32: Thank You
Thank You